Phase 3 Readout

BLRX: Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability

Name: Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability
Start: 2029-09-30
End: 2029-09-30

September 30, 2029. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: September 30, 2029
Company: BioLineRx Ltd. (BLRX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability

September 30, 2029

BLRX overview →

Company: BioLineRx Ltd. (BLRX)
Indication: Multiple Myeloma